[{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-EGFR antibodies","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity \/ Not Applicable"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharma Gets IND Authorization for its Multiple Myeloma Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STP705 Gets Orphan Drug Designation By US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics and Natera To Collaborate for ELI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics to Discuss Novel Lymph Node Vaccine Targeting Seven Key mKRAS Mutations at RAS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian angel investors","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian angel investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Pharmaceuticals \/ Canadian angel investors"},{"orgOrder":0,"company":"Amunix","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amunix Raises $73 Million in Series A Financing Led by Omega Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Amunix \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Omega Funds"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ 3SBio ","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3SBio "},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 Mutant KRAS Targeting Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from FDA for Initiating Clinical Trials for its Novel Monoclonal Antibody TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Announces Clearance of IND to Initiate Phase I\/II Study for First-in-Class PRGN-2009 AdenoVerse\u2122 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precigen \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Initiates IND-Enabling Activities For EDIT-201, An Allogeneic NK Cell Medicine For The Treatment Of Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1\/2 Trial of Lead Candidate ST101 in Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HJB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HJB & Mabspace Biosciences' Develop, Mfg Agreement for Novel Humanized Claudin1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized Claudin18.2 monoclonal antibody","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HJB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HFB301001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Presents Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells to Develop Engineered Cell Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals to Present Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1 beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent \/ Not Applicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Salinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Brown University Award of $3.4M includes funds for IND and First Clinical Trial of ONC212","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown University \/ Undisclosed"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx"},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CpG-STAT3siRNA","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Scopus BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Scopus BioPharma"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World's First iLDC Enabling ADC Drug Receives IND Clearance by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GQ1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Receives FDA IND Clearance to Initiate a Phase 1\/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T\u00ae for HER2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Files IND Application for GEN-011, a T cell Therapy Designed to Improve on Current Limitations of TIL Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JTX-1811","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTX-080","moa":"HLA-G","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tizona Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tizona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Announces FDA Allowance of IND for Phase 1a\/b Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptose Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentation of Preclinical Data for TransCon IL-2 \u03b2\/\u03b3 at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon IL-2 \u03b2\/\u03b3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Submits a CTA for a Phase I\/IIa trial of BI-1808","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1B","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FT819","moa":"CAR19 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo\u00ae (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genocea Announces Private Placement Financing of Up to $80 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Brookline Capital Markets"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Announces Receipt of IND Clearance to Conduct Window-of-Opportunity Trial of NT-I7 (efineptakin alfa) in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Launches Bright Peak Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"IL-2 conjugates","moa":"CD25 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics\u2019 First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Reveals Preclinical Data from COBRA\u2122 Program, MVC-280, at Virtual Cell Engager Summit 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 and Kymriah in Relapsed\/Refractory Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune\u2122 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210\/TJ210 in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab"},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Announces FDA Acceptance of Gen-011 IND Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ Not Applicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech\u2019s Investigational New Drug Application Placed on Hold by the U. S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-548","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Karolinska Development AB"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Announces Closing of $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptorum","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Oxular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OXU-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxular \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ Not Applicable"},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Therapeutics \/ PharmaEssentia"},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent to Present Data on BI-1808, an Anti-TNFR2 Antibody, at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent \/ Not Applicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Transfers OS Therapies' IND Application OST-HER2 (Listeria monocytogenes) to OS Therapies in Record Time","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OST-HER2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Submitts Investigational New Drug Application to FDA for the Second Drug Candidate from the PDC Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OPD5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptides \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b\/2 study for Etigilimab (Anti-TIGIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson Establishes new $50M+ Biotech Fund to Choose the Next Promising Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Cancer therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biopharma \/ MorphoSys"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic\u2122 Oncology Product Candidate for HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu-omburtamab-DTPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"enGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"enGene Gets FDA Clearance of IND Application for EG-70","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EG-70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"enGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"enGene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"enGene \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC\u2122 Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","amount":"$2,060.0 million","upfrontCash":"$60.0 million","newsHeadline":"Affimed and Roivant Sciences Ink Licensing Agreement to Develop and Commercialize Novel Innate Cell Engagers for Multiple Cancer Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":2.0600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0600000000000001,"dosageForm":"","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Roivant Sciences"},{"orgOrder":0,"company":"OneThree Biotech","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"JBI-802","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OneThree Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OneThree Biotech \/ Jubilant Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OneThree Biotech \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-668","moa":"IL4I1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calithera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EPCAM ProTriTAC\u2122 Program at 35th SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics Hauls in $300M IPO Just as Liso-Cel-Inspired CAR-T Nears the Finish Line in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Relmacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JW Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"JW Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The IND Application Of Henlius Daratumumab Biosimilar Accepted By NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Gets U.S. FDA IND Clearance for Phase 2 Study of NT-I7 and Atezolizumab Combo in First-line Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Presents New Preclinical Data on ATA3271 to Treat Solid Tumors, at the 35th SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA3271","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Inks Agreement with University of Michigan to Obtain an Exclusive License for a MDM2 Degrader Using PROTAC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MDM2 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"University of Michigan","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Michigan \/ Ascentage Pharma","highestDevelopmentStatusID":"5","companyTruncated":"University of Michigan \/ Ascentage Pharma"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$509.7 million","upfrontCash":"Undisclosed","newsHeadline":"Chordia and Ono Pharmaceutical Enter into Exclusive License Agreement on CTX-177, a MALT1 Inhibitor, and Other Related Compounds","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chordia Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Chordia Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$815.0 million","upfrontCash":"$85.0 million","newsHeadline":"Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SRF813","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Surface Oncology","amount2":0.81999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.81999999999999995,"dosageForm":"","sponsorNew":"Surface Oncology \/ GlaxoSmithKline","highestDevelopmentStatusID":"5","companyTruncated":"Surface Oncology \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Greater China and Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TG01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ IOVaxis","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis"},{"orgOrder":0,"company":"GX Acquisition","sponsor":"Celularity","pharmaFlowCategory":"D","amount":"$372.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Merger","leadProduct":"CYNK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GX Acquisition","amount2":0.37,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"","sponsorNew":"GX Acquisition \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"GX Acquisition \/ Celularity"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biomea Fusion Raises $56 Million to Bring First Irreversible Menin Inhibitor into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Irreversible menin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fusion \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Daratumumab Biosimilar Received IND Approval from NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria monocytogene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"TScan Therapeutics Announces $100 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"TSC-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ BlackRock"},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scopus BioPharma Announces Pricing of $9 Million Follow-On Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"CO-sTiRNA","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scopus Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Scopus Biopharma \/ The Benchmark Company","highestDevelopmentStatusID":"5","companyTruncated":"Scopus Biopharma \/ The Benchmark Company"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvalent Launches with $50M Series A Financing to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/ Deerfield Management"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA accepts Precision BioSciences\u2019 IND application for PBCAR19B to treat r\/r non-Hodgkin lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EU101","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ National OncoVenture"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cell Therapy Biotech Vor Biopharma Sets Terms for $150 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Engineered hematopoietic stem cell therapy","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vor Biopharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Vor Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"5","companyTruncated":"Vor Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EU101","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eutilex Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eutilex Inc \/ Samsung Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Eutilex Inc \/ Samsung Biologics"},{"orgOrder":0,"company":"BITT","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$125.6 million","upfrontCash":"Undisclosed","newsHeadline":"Boston Immune Technologies and Therapeutics and BeiGene Enter into an Option and License Agreement to Develop Novel TNFR2 Antagonists","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0.13,"therapeuticAreaNew":"Oncology","highestD
Market Place